Release-activity: A long way from phenomenon to new drugs

Bulletin of Experimental Biology and Medicine

Volumn 154, Issue 1, 2012, Pages 54-58

  Epstein, O I ^a  

^a Materia Medica Holding   (Russian Federation)

Author keywords

homeopathic dose; release active dilutions; release active preparations; release activity; ultralow dose

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; AMITRIPTYLINE; CYCLOPHOSPHAMIDE; DIAZEPAM; DICLOFENAC; GAMMA INTERFERON ANTIBODY; GLIBENCLAMIDE; HALOPERIDOL; INSULIN; LOSARTAN; METFORMIN; NEUROTROPIC AGENT; NEW DRUG; OSELTAMIVIR; PENTAZOCINE; PHENAZEPAM; POLYCLONAL ANTIBODY; PREDNISONE; PROTEIN S 100; RECOMBINANT ERYTHROPOIETIN; ROSIGLITAZONE; TETRAHYDROLIPSTATIN; TUMOR NECROSIS FACTOR ALPHA; ZIDOVUDINE; ANTIBODY; DRUG;

ADDICTION; ALCOHOLISM; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BASOPHIL DEGRANULATION; BIOLOGICAL ACTIVITY; CELL ACTIVITY; CLINICAL PRACTICE; CONCENTRATION (PARAMETERS); CONFORMATIONAL TRANSITION; DIABETES MELLITUS; DILUTION; DRUG DEPENDENCE; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG SAFETY; DRUG SPECIFICITY; DRUG TOLERANCE; HOMEOPATHY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOLECULAR MECHANICS; NERVE CELL MEMBRANE; NONHUMAN; OBESITY; PAIN THRESHOLD; PHYSICAL CHEMISTRY; POST TETANIC POTENTIATION; PROTEIN BINDING; PROTEIN HYDROLYSIS; PROTEIN TARGETING; RECEPTOR BINDING; SOLVATION; STRUCTURE ACTIVITY RELATION; TOBACCO DEPENDENCE; TRANQUILIZING ACTIVITY; ANIMAL; DOSE RESPONSE; HUMAN;

ANIMALS; ANTIBODIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HOMEOPATHY; HUMANS; PHARMACEUTICAL PREPARATIONS;

MLCS; MLOWN;

EID: 84877120112     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-012-1874-6     Document Type: Article

References (31)

1. N. V. Aleksandrova, A. G. Gofman, E. N. Krylov, and O. I. Epstein, Byull. Sib. Otd. Ross. Akad. Med. Nauk, No. 1, 94-98 (1999).
2. E. B. Burlakova, A. A. Konradova, and E. L. Mal'tseva, Khim. Fiz., 22, No. 2, 21-40 (2003)
3. E. B. Burlakova, Vestn. Ross. Akad. Nauk, 64, No. 5, 425-431 (1994)
4. T. P. Vetlugina, S. A. Ivanova, N. A. Bokhan, et al., in: Actua Problems in Psychiatry and Narcology [in Russian], Issue 11, Tomsk (2003), pp. 156-163.
5. V. G. Zilov, K. V. Sudakov, and O. I. Epstein, Elements of Informational Biology and Medicine [in Russian], Moscow, (2001).
6. G. V. Karpova, T. I. Fomina, T. V. Vetoshkina, et al., Byull. Eksp. Biol., 148, No. 3, 543-546 (2009).
7. A. M. Mkrtumyan, Effekt. Farmakoter. Endokrinol., No. 5, 2-10 (2011).
8. E. M. Molochkina, I. B. Ozerova, and E. B. Burlakova. Byull. Eksp. Biol., Suppl. 1, 48-50 (2003).
9. I. F. Pavlov and O. I. Epstein, Byull. Sib. Otd. Ross. Akad. Med. Nauk, No. 1, 92-94 (1999).
10. V. I. Petrov, V. V. Ivanenko, N. A. Davydova, et al., Serdechn. Nedostat., 8, No. 4, 175-177 (2007).
11. S. I. Petrov and O. I. Epstein, Byull. Eksp. Biol., Suppl. 1, 6-9 (2003).
12. S. A. Tarasov, M. V. Kachanova, E. A. Gorbunov, et al., Vestn. Mezhdunar. Akad. Nauk (Russ. Sect.), No. 1, 23-27 (2010).
13. S. A. Tarasov, M. V. Mashkina, Yu. O. Akindinova, et al., in: Immunophysiology: Natural Immunity in Norm and Pathology, Eds. A. B. Poletaev and A. N. Danilova [in Russian], Moscow (2008), pp. 203-205.
14. M. B. Shtark and O. I. Epstein (Eds.), Byull. Eksp. Biol., Suppl. 4, (2002).
15. M. B. Shtark and O. I. Epstein (Eds.), Byull. Eksp. Biol., Suppl. 1, (2003).
16. M. B. Shtark and S. A. Sergeeva (Eds.), Byull. Eksp. Biol., Suppl. 1, (2009).
17. O. I. Epstein, Ultralow Doses: History of a Study [in Russian], Moscow (2008).
18. O. I. Epstein, Medicinal drug. Patent of RF, No. 2084217. 20.07.97. Bull. No. 20.
19. O. I. Epstein, N. A. Beregovoi, N. S. Sorokina, et al., Byull. Eksp. Biol., 127, No. 3, 317-320 (1999).
20. O. I. Epstein, T. M. Vorob'eva, O. G. Berchenko, et al., in: Informational and Ontological Models of Adaptation, Ed. O. I. Epstein [in Russian], Moscow (1997).
21. O. I. Epstein, T. M. Vorob'eva, V. V. Geiko, and O. G. Berchenko, Byull. Eksp. Biol., Suppl. 1, 45-47 (2003).
22. O. I. Epstein, Kh. L. Gainutdinov, and M. B. Shtark, Byull. Eksp. Biol., 127, No. 4, 466-467 (1999).
23. O. I. Epstein, E. Yu. Sherstoboev, A. V. Martyushev-Poklad, et al., Byull. Eksp. Biol., 137, No. 5, 527-529 (2004).
24. O. I. Epstein, M. B. Shtark, A. M. Dygai, et al., Pharmacology of Ultralow Doses of Antibodies to Endogenous Functional Regulators [in Russian], Moscow (2005).
25. O. I. Epstein, M. B. Shtark, A. Kh. Timoshenko, et al., Byull. Eksp. Biol., 143, No. 5, 490-493 (2007).
26. E. Davenas, F. Beauvais, J. Amara, et al., Nature, 333, 816-818 (1988).
27. O. I. Epstein, N. A. Beregovoi, N. S. Sorokina, et al., Front. Biosci., 8, A79-A84 (2003).
28. J. Maddox, J. Randi, and W. W. Stewart, Nature, 334, 287-291 (1988).
29. Y. Shoenfeld and D. A. Isenberg, Natural Autoantibodies: Their Physiological Role and Regulatory Signifi cance, Boca Raton, (1993).
30. S. A. Tarasov, V. V. Zarubaev, E. A. Gorbunov, et al., Antiviral Res., 93, No. 2, 219-224 (2012).
31. T. A. Voronina, S. A. Sergeeva, A. V. Martyushev-Poklad, et al., in: Animal Models in Biological Psychiatry, Ed. A. V. Kalueff, Nova Science Publishers (2006), pp. 137-152.